Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.
NCT ID: NCT02288273
Last Updated: 2017-01-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
239 participants
INTERVENTIONAL
2014-12-31
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Specific Clinical Experience Investigation for Long-term Use of Bydureon.
NCT01940770
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
NCT00039013
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
NCT02434744
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus
NCT00035984
Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus
NCT00458016
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bydureon
Once weekly injected exenatide
Bydureon
Once weekly injection of 2mg bydureon (extended release exenatide) for 10 weeks.
Placebo
Placebo comparator
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bydureon
Once weekly injection of 2mg bydureon (extended release exenatide) for 10 weeks.
Placebo
Placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hemoglobin A1c (HbA1c) 7% to 10% at screening
* Body mass index (BMI) \< or = to 45 kg/m2
Exclusion Criteria
* History of taking a dipeptidyl peptidase-4 (DPP-4) inhibitor or pramlintide during 12 weeks prior to screening
* History of potent, inhaled or intrapulmonary steroids 3 months prior to screening or during the study
* History of prescription or over the counter weight loss medication during 3 months prior to screening
* Previous exposure to exenatide or any glucagon-like peptide-1 (GLP-1) receptor agonist during 6 months prior to screening
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Anaheim, California, United States
Research Site
Chino, California, United States
Research Site
Los Angeles, California, United States
Research Site
North Hollywood, California, United States
Research Site
Santa Ana, California, United States
Research Site
Spring Valley, California, United States
Research Site
Tustin, California, United States
Research Site
Walnut Creek, California, United States
Research Site
Hollywood, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Port Orange, Florida, United States
Research Site
Marietta, Georgia, United States
Research Site
Chicago, Illinois, United States
Research Site
Edina, Minnesota, United States
Research Site
St Louis, Missouri, United States
Research Site
Butte, Montana, United States
Research Site
Las Vegas, Nevada, United States
Research Site
Franklin, Ohio, United States
Research Site
Marion, Ohio, United States
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Mt. Pleasant, South Carolina, United States
Research Site
Rapid City, South Dakota, United States
Research Site
Corpus Christi, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Katy, Texas, United States
Research Site
Salt Lake City, Utah, United States
Research Site
Burke, Virginia, United States
Research Site
Manassas, Virginia, United States
Research Site
Olympia, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D5551L00006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.